Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $170.00 Price Target at JPMorgan Chase & Co.

Alnylam Pharmaceuticals (NASDAQ:ALNYFree Report) had its price target upped by JPMorgan Chase & Co. from $150.00 to $170.00 in a research note released on Thursday morning, Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the biopharmaceutical company’s stock.

ALNY has been the subject of a number of other research reports. Evercore ISI cut their price target on Alnylam Pharmaceuticals from $252.00 to $210.00 in a research note on Tuesday, October 10th. Citigroup decreased their target price on shares of Alnylam Pharmaceuticals from $266.00 to $233.00 and set a buy rating for the company in a research note on Tuesday, October 10th. Royal Bank of Canada dropped their price target on shares of Alnylam Pharmaceuticals from $235.00 to $230.00 and set an outperform rating on the stock in a research note on Friday, November 3rd. Piper Sandler boosted their price objective on shares of Alnylam Pharmaceuticals from $210.00 to $217.00 and gave the company an overweight rating in a research report on Thursday, December 14th. Finally, Morgan Stanley raised their price target on shares of Alnylam Pharmaceuticals from $175.00 to $183.00 and gave the company an equal weight rating in a research report on Friday, November 3rd. Six analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and an average target price of $230.95.

Check Out Our Latest Research Report on ALNY

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $173.06 on Thursday. The firm has a market cap of $21.72 billion, a price-to-earnings ratio of -41.80 and a beta of 0.43. The business’s 50-day simple moving average is $183.20 and its 200-day simple moving average is $180.41. Alnylam Pharmaceuticals has a 52 week low of $148.10 and a 52 week high of $234.70.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of ($1.61) by $2.76. The firm had revenue of $750.53 million during the quarter, compared to the consensus estimate of $406.14 million. As a group, equities research analysts forecast that Alnylam Pharmaceuticals will post -3.47 earnings per share for the current year.

Insider Activity

In other Alnylam Pharmaceuticals news, Director Michael W. Bonney sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, December 27th. The shares were sold at an average price of $195.00, for a total value of $5,850,000.00. Following the completion of the sale, the director now owns 16,029 shares of the company’s stock, valued at $3,125,655. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently bought and sold shares of ALNY. Raymond James Financial Services Advisors Inc. raised its stake in Alnylam Pharmaceuticals by 9.4% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 11,850 shares of the biopharmaceutical company’s stock worth $1,935,000 after buying an additional 1,017 shares in the last quarter. MetLife Investment Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the first quarter valued at $1,268,000. Panagora Asset Management Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 96.4% during the first quarter. Panagora Asset Management Inc. now owns 6,565 shares of the biopharmaceutical company’s stock valued at $1,072,000 after buying an additional 3,223 shares during the last quarter. Great West Life Assurance Co. Can lifted its position in Alnylam Pharmaceuticals by 21.2% during the first quarter. Great West Life Assurance Co. Can now owns 62,369 shares of the biopharmaceutical company’s stock valued at $10,786,000 after purchasing an additional 10,892 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in Alnylam Pharmaceuticals by 1.2% during the first quarter. Dimensional Fund Advisors LP now owns 181,271 shares of the biopharmaceutical company’s stock valued at $29,601,000 after purchasing an additional 2,111 shares during the period. Institutional investors own 93.98% of the company’s stock.

About Alnylam Pharmaceuticals

(Get Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Featured Stories

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.